Enhancing FCPA and Anti- Corruption Compliance for Life Sciences 2014

With the Vice Presidents, Directors, Heads, Chief Compliance Officers, and In-house Counsel from cross-industry sectors:
Anti-Corruption, Ethics and Compliance, FCPA Compliance, Anti-Bribery,
Regulatory Affairsheavy pursuit of life sciences continuing to grow by regulators, it is imperative to be prepared to endure a possible investigation.

Our experienced team of dedicated professionals deliver top-level networking environments and provide new interactive dimensions in event management for the North American region.

LEARNING OBJECTIVES
• Keep abreast of global regulation reform: an update on BRIC country anti-bribery acts
• Dissect the GSK case: what outcomes can you anticipate integrating to your program?
• Proactively prepare response techniques for when an international investigation may strike
• Streamline third party due diligence and HCP oversight globally
• Strengthen controls surrounding foreign clinical trials
• Develop effective techniques for conducting an extraterritorial CRO audit
• Deploy a global training program throughout the extended enterprise
• Hear the latest developments in conducting fool proof monitoring and auditing
• Gain information on the latest enforcement trends to avoid non-compliance
• Operationalize the compliance program to follow business venture activities: M&A due diligence
• Incorporating data analytics: exploring complexities of internal or external investigations in the digital age
• Mitigate risks manifesting from marketing and sales distribution channel